MolDX: Genetic Testing for Hereditary Thrombophilia

Hereditary germline genetic testing for thrombophilia is covered only when the patient has VTE in specific clinical contexts (VTE associated with non-surgical major transient or hormonal risk factors per ASH, or cerebral/splanchnic venous thrombosis where results will affect long-term anticoagulation decisions), and when testing will guide clinical management. Tests must include ASH-guideline–supported gene/variant content, be properly validated (no unvalidated additional content), may be single-variant if it is a known familial variant, must not conflict with policy L38288, and must have satisfactorily completed a MolDX Technical Assessment.

"Genetic testing is covered when the patient presents with venous thromboembolism (VTE) and the VTE is associated with non-surgical major transient or hormonal risk factors as defined by American So..."

Sign up to see full coverage criteria, indications, and limitations.